Chemotherapeutics, chemoresistance and the management of melanoma

Giornale Italiano di Dermatologia e Venereologia

Volumn 144, Issue 1, 2009, Pages 61-78

  Rass, K ^a   Hassel, J C ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Apoptosis Genes, bcl 2; DNA repair; Drug resistance, multiple; Drug therapy; Melanoma, physiopatology; Mitogen activated protein kinase 1; Neoplastic stem cells; Protein kinase inhibitors

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DOCETAXEL; FOTEMUSTINE; HYDROXYUREA; INTERLEUKIN 2; LOMUSTINE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OBLIMERSEN; PACLITAXEL; PEGINTERFERON ALPHA2B; PLACEBO; RAPAMYCIN; SORAFENIB; TAMOXIFEN; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

ADJUVANT THERAPY; ADVANCED CANCER; APOPTOSIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DNA REPAIR; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG TARGETING; HUMAN; HYPERTHERMIC THERAPY; LOW DRUG DOSE; LYMPH NODE METASTASIS; MELANOMA; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; SYSTEMATIC REVIEW; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

EID: 66549117524     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Physiol 2001;14:280-290 (Pubitemid 34701635)
2. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 2007;17:117-127
3. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3636
4. Rass K, Tilgen W. Treatment of melanoma and non-melanoma skin cancer. Adv Exp Med Biol 2008;624:296-318.
5. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138-3151
6. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-4745
7. Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988;318:1159-1162 (Pubitemid 18117695)
8. Ringborg U, Andersson R, Eldh J, Glaumann B, Hafström L, Jacobsson S et al. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer 1996;77:1809-1814
9. Garbe C, Schadendorf D, Stolz W, Volkenandt M, Reinhold U, Kortmann RD et al. Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges 2008;6(Suppl 1):9-14.
10. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-399
11. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial. Lancet 1998;351:793-796 (Pubitemid 28112341)
12. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307-1317
13. McLoughlin JM, Zager JS, Sondak VK, Berk LB. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control 2008;15:239-247
14. Leo F, Cagini L, Rocmans P, Cappello M, Geel AN, Maggi G et al. Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer 2000;83:596-672
15. Tagawa ST, Cheung E, Banta W, Gee C, Weber JS. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer 2006;106:1353-1357 (Pubitemid 43363914)
16. Wornom IL 3rd, Smith JW, Soong SJ, McElvein R, Urist MM, Balch CM. Surgery as palliative treatment for distant metastases of melanoma. Ann Surg 1986;204:181-185
17. Eggermont AMM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005;366:1189-96.
18. Eggermont AMM, Suciu S, Santinami M, Testori A, Kruit WHJ, Marsden J et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372:117-126
19. Hauschild A, Rass K, Tilgen W. Systemic treatment of melanoma. Current clinical trials. Hautarzt 2008;59:484-492
20. Lens MB, Dawes M. Interferon alpha therapy for malignant melanoma: A systemic review of randomized controlled trials. J Clin Oncol 2002;20:1818-1825 (Pubitemid 34273271)
21. Wheatley K, Ives H, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003;29:241-252 (Pubitemid 37069655)
22. Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recunent melanoma. Cancer 2006;106:1431-1442
23. Wheatley K, Ives N, Eggermont AM, Kirkwood J, Cascinelli N, Markovic SN et al. Interferon- as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. Proc Am Soc Clin Oncol 2007;25:8526.
24. Eggermont AMM, Gore M. Randomized adjuvant therapy trials in melanoma: surgical and systemic. Semin Oncol 2007;34:509-515 (Pubitemid 350245676)
25. Eigentler TK, Radny P, Hauschild A, Gutzmer R, Linse R, Pföhler C et al. Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. Melanoma Res 2008;18:353-358
26. Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J et al. Adjuvant low-dose interferon ·2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 2008;19:1195-1201
27. Stadler R, Luger T, Bieber T, Köhler U, Linse R, Technau K et al. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial. Acta Oncol 2006;45:389-399
28. Noorda EM, Vrouenraets BC, Nieweg OE, van Geel BN, Eggermont AM, Kroon BB. Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 2004;139:1237-1242 (Pubitemid 39463461)
29. Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter reandomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998;16:2906-2912
30. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4:748-759 (Pubitemid 37527210)
31. Rass K, Tadler D, Tilgen W. Therapy of malignant melanoma. First-, second-, and pathogenesis-oriented third-line therapies. Hautarzt 2006;57:773-784
32. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007;109:455-464
33. Eggermont AMM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastastic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40:1825-1836
34. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563-570
35. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastastatic melanoma. J Clin Oncol 2000;18:158-166
36. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase II study. J Clin Oncol 2004;22:1118-1125
37. Moreno-Aspitia A, Perez EA. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer. Future Oncol 2005;1:755-762
38. Hersh E, O'Day S, Gonzales R, Ribas A, Samlowski W, Gordon M. Phase II trial of ABI-007 (Abraxane) in previously treated and chemotherapy naive patients with metastatic melanoma. Melanoma Res 2006;16 (Suppl 1):78.
39. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:1752-1759 (Pubitemid 28234719)
40. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:2045-2052
41. Ugurel S, Schadendorf D, Pföhler C, Neuber K, Thoelke A, Ulrich J et al. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multcenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res 2006;12:5454-5463
42. Kadekaro AL, Wakamatsu K, Ito S, Abdel-Malek ZA. Cutaneous photoprotection and melanoma susceptibility: reaching beyond melanin content to the frontiers of DNA repair. Front Biosci 2006;11:2157-73. (Pubitemid 43832721)
43. Campioni M, Santini D, Tonini G, Murace R, Dragonetti E, Spugnini EP, Baldi A. Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance. Exp Dermatol 2005;14:811-8.
44. Leiter U, Schmid RM, Kaskel P, Peter RU, Krahn G. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res 2000;292:225-232 (Pubitemid 30265047)
45. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, Hersey P. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol 2007;20:416-26. (Pubitemid 46482365)
46. Hassel JC, Winnemöller D, Schartl M, Wellbrock C. STAT5 contributes to anti-apoptosis in melanoma. Melanoma Res 2008;18:378-385
47. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
48. Curtin JA, Fridlyand J, Kageshita R, Patel HN, Busam KJ, Kutzner H et al. Distinct sets of genetic alteration in melanoma. N Engl J Med 2005;353:2135-2147
49. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996;87:629-638 (Pubitemid 26386937)
50. Sheridan C, Brumatti G, Martin SJ. Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim. J Biol Chem 2008;283:22128-22135
51. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 2003;63:1639-1643 (Pubitemid 36373656)
52. Reifenberger J, Knobbe CB, Sterzinger AA, Blaschke B, Schulte KW, Ruzicka T, Reifenberger G. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 2004;109:377-384 (Pubitemid 38252766)
53. Mirmohammadsadegh A, Mota R, Gustrau A, Hassan M, Nambiar S, Marini A et al. ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol 2007;127:2207-2215
54. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 2004;6:7099-109.
55. Agarwala SS, Keilholz U, Hogg D, Robert C, Hersey P, Eggermont A et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J Clin Oncol ASCO Annual Meeting Proceedings 2007;25:8510.
56. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 study group. J Clin Oncol 2008;26:2178-2185
57. Becker JC, Kirkwood JM, Agarwala SS, Dummer R, Schrama D, Hauschild A. Molecular targeted therapy for melanoma - current reality and future options. Cancer 2006;107:2317-2327 (Pubitemid 44748514)
58. Haluska F, Pemberton T, Ibrahim N, Kalinsky K. The RTT/RAS/BRAF/PI3K pathways in melanoma: Biology, small molecule inhibitors, and potential applications. Semin Oncol 2007;34:546-54. (Pubitemid 350236312)
59. Blanco-Aparicio C, Renner O, Leal JFM, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007;28:1379-1386 (Pubitemid 47243536)
60. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist Bad in response to survival factor results in binding to 14-3-3 not Bcl-X. Cell 1996;87:619-628 (Pubitemid 26386936)
61. Hersey P. Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma. Curr Opin Oncol 2006;18:189-196 (Pubitemid 43740441)
62. Chekenya M, Krakstad C, Svendsen A, Netland KE, Staalesen V, Tysenes BB et al. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene 2008;27:5182-5194
63. Marshall J, Posey J, Hwang J, Malik S, Shen R, Kazempour K et al. A phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer. J Clin Oncol ASCO Annual Meeting Proceedings 2007;25:3564.
64. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005;104:1045-1048
65. Thallinger C, Poeppl W, Pratscher B, Mayerhofer M, Valent P Tappeiner G, Joukhadar C. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotransplantation model. Pharmacology 2007;79:207-213
66. Lasithiotakis KG, Sinnberg TW, Schnittek B, Flaherty KT, Kulms D, Maczey E et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 2008;128:2013-2023
67. Trisciuoglio D, Iervoline A, Zupi G, Del Bufalo D. Involvement of PI3K and MAPK signalling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol Biol Cell 2005;16:4153-4162 (Pubitemid 41262885)
68. Tarhini AA, Kirkwood JM. Oblimerson in the treatment of metastatic melanoma. Future Oncol 2007;3:263-271 (Pubitemid 47022844)
69. Engels K, Knauer sK, Loibl S, Fetz V, Harter P, Schweitzer A et al. NOno signaling confers cytoprotectivity through the survivin network in ovarian carcinomas. Cancer Res 2008;68:5159-5166
70. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Müller M et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998;4:232-234
71. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435:677-681
72. Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS et al. 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 2008;14:1256-1263
73. Anderson MH, Svane IM, Becker JC, Straten PT. The universal character of the tumor-associated antigen survivin. Clin Cancer Res 2007;13:5991-5994 (Pubitemid 350075053)
74. Amiri KI, Richmond A. Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev 2005;24:301-313
75. Dhawan P, Su Y, Thu YM, Yu Y, Baugher P, Ellis DL et al. The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells. J Biol Chem 2008;283:15399-15408
76. Gruber BM, Anuszewska EL, Bubko I, Kasprzycka-Guttman T, Misiewicz I, Skupifska K et al. NFkappaB activation and drug sensitivity in human neoplastic cells treated with anthracyclines. Acta Pol Pharm 2008;65:267-271
77. Schön M, Wienrich BG, Kneitz S, Sennefelder H, Amschler K, Vöhringer V et al. KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment. J Natl Cancer Inst 2008;100:862-875
78. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. J Pathol 2003;199:275-288
79. Marin YE, Wall BA, Wang S, Namkoong J, Martino JJ, Suh J et al. Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells. Melanoma Res 2007;17:274-283
80. Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A. Augmenting chemosensitivity of malignant melanoma tumours via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 2004;64:4912-4918 (Pubitemid 38924537)
81. Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 2005;103:2584-2589
82. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-211
83. Karst AM, Dai LD, Martinska M, Li G. PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene 2005;24:1111-1116 (Pubitemid 40313889)
84. Fecker LF, Geilen CC, Tchernerv G, Trefzer U, Assaf C, Kurbanov BM et al. Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol 2006;126:1366-1371
85. Schwartz MA, McRoberts K, Coyner M, Andarawewa KL, Frierson HF, Sanders JM et al. Integrin agonists as adjuvants in chemotherapy for melanoma. Clin Cancer Res 2008;14:6193-6197
86. Tarhini AA, Agarwala SS. Novel agents in development for the treatment of melanoma. Expert Opin Investig Drugs 2005;14:885-892 (Pubitemid 41030955)
87. Rapp M, Maurizis JC, Papon J, Labarre P, Wu TD, Croisy A et al. A new O6-aklylguanine-DNA alkyltransferase inhibitor associated with a nitrosourea (cystemustine) validates a strategy of melanoma-targeted therapy in murine B16 and human-resistant M4Beu melanoma xenograft models. J Pharmacol Exp Ther 2008;326:171-177
88. Hegi ME, Diserens AC, Gorlia T, Harnou MF, de Tribolet N, Weller M et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003.
89. Middleton MR, Lunn JM, Morris C, Rustin G, Wedge SR, Brampton MH et al. O6-methylguanine-DNA methyltransferase in pre-treatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998;79:1199-1202
90. Ma S, Egyhazi S, Ueno T, Lindholm C, Kreklau EL, Stierner U et al. O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer 2003;89:1517-1523
91. Tawbi HA, Kirkwood JM. Management of metastatic melanoma. Semin Oncol 2007;34:532-545 (Pubitemid 350236308)
92. Tentori L, Leonetti C, Scarsella M, Vergati M, Xu W, Calvin D et al. Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. Int J Oncol 2005;26:415-422
93. La Porta CAM. Drug resistance in melanoma: new perspectives. Curr Med Chem 2007;14:387-391 (Pubitemid 46299686)
94. Liedert B, Materna V, Schadendorf D, Thomale J, Lage H. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-Arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 2003;121:172-176 (Pubitemid 36900469)
95. Deichmann M, Thome M, Egner U, Hartschuh W, Kurzen H. The chemoresistance gene ABCG2 (MXR/BCRP1/ABCP1) is not expressed in melanomas but in single neuroendocrine carcinomas of the skin. J Cutan Pathol 2005;32:467-473 (Pubitemid 41039396)
96. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007;43:935-946
97. Singhal SS, Singhal J, Yadav S, Dwivedi S, Boor PJ, Awasthi YC, Awasthi S. Regression of lung and colon cancer xenografts by depleting or inhibitin RLIP76 (Ral-bindinb protein 1). Cancer Res 2007;76:4382-4389
98. Singhal SS, Awasthi YC, Awasthi S. Regression of melanoma in a murine model by RLIP76 depletion. Cancer Res 2006;66:2354-2360 (Pubitemid 43294950)
99. Nishimura EK, Jordan SA, Oshima H, Yoshida H, Osawa M, Moryama M et al. Dominant role of the niche in melanocyte stem-cell fate determination. Nature 2002;416:854-860
100. Strizzi L, Abbott DE, Salomon DS, Hendrix MJC. Potential for Cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle 2008;7:1931-1935
101. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005;65:9328-9337
102. Kayo H, Yamazaki H, Nishida H, Dang NH, Morimoto C. Stem cell properties and the side population cells as a target for interferon-alpha in adult T-cell leukaemia/lymphoma. Biochem Biophys Res Coram 2007;364:808-814 (Pubitemid 350087873)